Literature DB >> 16284725

Monoclonal antibodies against soybean Bowman-Birk inhibitor recognize the protease-reactive loops.

Yifan Mao1, Cindy Lai, Gudrun Vogtentanz, Brian Schmidt, Tony Day, Jeff Miller, David L Brandon, Dan Chen.   

Abstract

Monoclonal antibodies against soybean Bowman-Birk protease inhibitor (BBI) have been generated and used to detect and quantify BBI in foods, soybean germplasm, and animal tissues and fluids. The purpose of this study was to determine the recognition sites of two monoclonal antibodies to BBI (mAb 238 and mAb 217) in relation to the protease-inhibitory sites of BBI. The results showed that (1) the binding of mAb 238 can be blocked by trypsin and that of mAb 217 by chymotrypsin; (2) the trypsin or chymotrypsin inhibitory activities of BBI are blocked by mAb 238 or mAb 217, respectively; and (3) mAb 238 failed to recognize a tryptic loop mutant BBI variant and mAb 217 was unable to bind a chymotryptic loop mutant BBI variant. These findings demonstrate that the epitopes recognized by mAb 238 and mAb 217 reside, at least in part, in the tryptic and chymotryptic loops of BBI, respectively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284725     DOI: 10.1007/s10930-005-6748-6

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  22 in total

1.  Crystal structure of cancer chemopreventive Bowman-Birk inhibitor in ternary complex with bovine trypsin at 2.3 A resolution. Structural basis of Janus-faced serine protease inhibitor specificity.

Authors:  J Koepke; U Ermler; E Warkentin; G Wenzl; P Flecker
Journal:  J Mol Biol       Date:  2000-05-05       Impact factor: 5.469

2.  Reactive sites of an anticarcinogenic Bowman-Birk proteinase inhibitor are similar to other trypsin inhibitors.

Authors:  P Chen; J Rose; R Love; C H Wei; B C Wang
Journal:  J Biol Chem       Date:  1992-01-25       Impact factor: 5.157

3.  Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial.

Authors:  W B Armstrong; A R Kennedy; X S Wan; T H Taylor; Q A Nguyen; J Jensen; W Thompson; W Lagerberg; F L Meyskens
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

4.  Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis.

Authors:  J H Ware; X S Wan; P Newberne; A R Kennedy
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

5.  Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells.

Authors:  Ann R Kennedy; X Steven Wan
Journal:  Prostate       Date:  2002-02-01       Impact factor: 4.104

6.  ELISA analysis of soybean trypsin inhibitors in processed foods.

Authors:  D L Brandon; A H Bates; M Friedman
Journal:  Adv Exp Med Biol       Date:  1991       Impact factor: 2.622

7.  Detection of Bowman-Birk inhibitor and anti-Bowman-Birk inhibitor antibodies in sera of humans and animals treated with Bowman-Birk inhibitor concentrate.

Authors:  X Steven Wan; David G Serota; Jeffrey H Ware; James A Crowell; Ann R Kennedy
Journal:  Nutr Cancer       Date:  2002       Impact factor: 2.900

8.  Bowman-Birk protease inhibitor and its palmitic acid conjugate prevent 7,12-dimethylbenz[a]anthracene-induced transformation in cultured mouse mammary glands.

Authors:  X Du; K Beloussow; W C Shen
Journal:  Cancer Lett       Date:  2001-03-26       Impact factor: 8.679

9.  Chymotrypsin-specific protease inhibitors decrease H2O2 formation by activated human polymorphonuclear leukocytes.

Authors:  K Frenkel; K Chrzan; C A Ryan; R Wiesner; W Troll
Journal:  Carcinogenesis       Date:  1987-09       Impact factor: 4.944

10.  Inhibition of N-nitrosomethylbenzylamine-induced esophageal neoplasms by the Bowman-Birk protease inhibitor.

Authors:  E von Hofe; P M Newberne; A R Kennedy
Journal:  Carcinogenesis       Date:  1991-11       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.